{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:09:26Z","timestamp":1763194166423,"version":"3.45.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.7759\/cureus.96878","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:05:06Z","timestamp":1763193906000},"source":"Crossref","is-referenced-by-count":0,"title":["Nasal Adverse Events Associated With Attention-Deficit Hyperactivity Disorder (ADHD) Medications: A Systematic Review, Meta-Analysis, and Implications for the Otolaryngologist"],"prefix":"10.7759","author":[{"given":"Tasnim","family":"Kamal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.09.2206","article-title":"Understanding attention-deficit\/hyperactivity disorder from childhood to adulthood","volume":"122","author":"Wilens TE","year":"2010","unstructured":"Wilens TE, Spencer TJ. Understanding attention-deficit\/hyperactivity disorder from childhood to adulthood. Postgrad Med. 2010, 122:97-109. 10.3810\/pgm.2010.09.2206","journal-title":"Postgrad Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115449","article-title":"Prevalence of attention deficit hyperactivity disorder in adults: umbrella review of evidence generated across the globe","volume":"328","author":"Ayano G","year":"2023","unstructured":"Ayano G, Tsegay L, Gizachew Y, et al.. Prevalence of attention deficit hyperactivity disorder in adults: umbrella review of evidence generated across the globe. Psychiatry Res. 2023, 328:115449. 10.1016\/j.psychres.2023.115449","journal-title":"Psychiatry Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1343314","article-title":"The impacts associated with having ADHD: an umbrella review","volume":"15","author":"French B","year":"2024","unstructured":"French B, Nalbant G, Wright H, et al.. The impacts associated with having ADHD: an umbrella review. Front Psychiatry. 2024, 15:1343314. 10.3389\/fpsyt.2024.1343314","journal-title":"Front Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02228-3","article-title":"Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study","volume":"28","author":"Cortese S","year":"2023","unstructured":"Cortese S, Song M, Farhat LC, et al.. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. Mol Psychiatry. 2023, 28:4823-30. 10.1038\/s41380-023-02228-3","journal-title":"Mol Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.512","article-title":"Attention-deficit hyperactivity disorder diagnoses and prescriptions in UK primary care, 2000-2018: population-based cohort study","volume":"9","author":"McKechnie DG","year":"2023","unstructured":"McKechnie DG, O'Nions E, Dunsmuir S, Petersen I. Attention-deficit hyperactivity disorder diagnoses and prescriptions in UK primary care, 2000-2018: population-based cohort study. BJPsych Open. 2023, 9:e121. 10.1192\/bjo.2023.512","journal-title":"BJPsych Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1066988","article-title":"Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials","volume":"13","author":"Nazarova VA","year":"2022","unstructured":"Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schi\u00f6th HB. Treatment of ADHD: drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022, 13:1066988. 10.3389\/fphar.2022.1066988","journal-title":"Front Pharmacol"},{"key":"ref7","unstructured":"Methylphenidate for ADHD. mechanism of action and formulations. (2025). Accessed: October 18, 2025: https:\/\/psychopharmacologyinstitute.com\/publication\/methylphenidate-for-adhd-mechanism-of-action-and-formulations-2194\/."},{"key":"ref8","unstructured":"Stimulant and non-stimulant agents for ADHD. (2025). Accessed. October 18, 2025: https:\/\/pharmaceutical-journal.com\/article\/ld\/stimulant-and-non-stimulant-agents-for-adhd."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese S","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, et al.. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018, 5:727-38. 10.1016\/S2215-0366(18)30269-4","journal-title":"Lancet Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301164","article-title":"Stimulants: therapeutic actions in ADHD","volume":"31","author":"Arnsten AF","year":"2006","unstructured":"Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006, 31:2376-83. 10.1038\/sj.npp.1301164","journal-title":"Neuropsychopharmacology"},{"key":"ref11","unstructured":"Intuniv. a different approach to ADHD treatment. (2023). Accessed: October 18, 2025: https:\/\/www.child-adolescentadhd.co.uk\/intuniv."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1753465811403348","article-title":"Nasal obstruction as a drug side effect","volume":"5","author":"Cingi C","year":"2011","unstructured":"Cingi C, Ozdoganoglu T, Songu M. Nasal obstruction as a drug side effect. Ther Adv Respir Dis. 2011, 5:175-82. 10.1177\/1753465811403348","journal-title":"Ther Adv Respir Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.6.783","article-title":"Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use","volume":"5","author":"Pass\u00e0li D","year":"2006","unstructured":"Pass\u00e0li D, Salerni L, Pass\u00e0li GC, Pass\u00e0li FM, Bellussi L. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf. 2006, 5:783-90. 10.1517\/14740338.5.6.783","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","unstructured":"Attention deficit hyperactivity disorder. methylphenidate. (2025). Accessed: October 19, 2025: https:\/\/cks.nice.org.uk\/topics\/attention-deficit-hyperactivity-disorder\/prescribing-information\/methylphenidate\/."},{"key":"ref15","unstructured":"Strattera (atomoxetine HCl). (2022). Accessed. October 19, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21411_strattera_lbl.pdf."},{"key":"ref16","unstructured":"Concerta side effects. common, severe, long term. (2024). Accessed: October 19, 2025: https:\/\/www.drugs.com\/sfx\/concerta-side-effects.html."},{"key":"ref17","unstructured":"R\/ADHD on Reddit. DAE have weird sinus issues on meds?. (2011). Accessed: October 19, 2025: https:\/\/www.reddit.com\/r\/ADHD\/comments\/uoc9r\/dae_have_weird_sinus_issues_on_meds\/."},{"key":"ref18","unstructured":"R\/ADHD on Reddit. Help! Adderall & sinuses?. (2021). Accessed: October 19, 2025: https:\/\/www.reddit.com\/r\/ADHD\/comments\/qm8goq\/help_adderall_sinuses\/."},{"key":"ref19","unstructured":"R\/ADHD on Reddit. fairly certain Vyvanse is causing thick mucus\/phlegm. (2025). Accessed: October 19, 2025: https:\/\/www.reddit.com\/r\/ADHD\/comments\/1i6t85w\/fairly_certain_vyvanse_is_causing_thick_mucus\/."},{"key":"ref20","unstructured":"Nasal congestion. (2011). Accessed. October 19, 2025: https:\/\/totallyadd.com\/forums\/forums\/topic\/nasal-congestion\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001131","article-title":"Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD","volume":"15","author":"Buitelaar JK","year":"2012","unstructured":"Buitelaar JK, Trott GE, Hofecker M, Waechter S, Berwaerts J, Dejonkheere J, Sch\u00e4uble B. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol. 2012, 15:1-13. 10.1017\/S1461145711001131","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(14)70324-4","article-title":"P.1.g.013 Efficacy and safety of methylphenidate modified release long-acting after reinstatement of therapy in placebo treated patients","volume":"24","author":"Huss M","year":"2014","unstructured":"Huss M, Ginsbery Y, Arngrim T, et al.. P.1.g.013 Efficacy and safety of methylphenidate modified release long-acting after reinstatement of therapy in placebo treated patients. Eur Neuropsychopharmacol. 2014, 24:209-10. 10.1016\/S0924-977X(14)70324-4","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s6873","article-title":"Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder","volume":"5","author":"Buitelaar JK","year":"2009","unstructured":"Buitelaar JK, Ramos-Quiroga JA, Casas M, et al.. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit\/hyperactivity disorder. Neuropsychiatr Dis Treat. 2009, 5:457-66. 10.2147\/ndt.s6873","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2011.600333","article-title":"Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit\/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study","volume":"14","author":"Casas M","year":"2013","unstructured":"Casas M, R\u00f6sler M, Sandra Kooij JJ, et al.. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit\/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry. 2013, 14:268-81. 10.3109\/15622975.2011.600333","journal-title":"World J Biol Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2013.868925","article-title":"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit\/hyperactivity disorder in Japan","volume":"15","author":"Takahashi N","year":"2014","unstructured":"Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit\/hyperactivity disorder in Japan. World J Biol Psychiatry. 2014, 15:488-98. 10.3109\/15622975.2013.868925","journal-title":"World J Biol Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0180-4","article-title":"Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study","volume":"28","author":"Ginsberg Y","year":"2014","unstructured":"Ginsberg Y, Arngrim T, Philipsen A, Gandhi P, Chen CW, Kumar V, Huss M. Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study. CNS Drugs. 2014, 28:951-62. 10.1007\/s40263-014-0180-4","journal-title":"CNS Drugs"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0085-5","article-title":"Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial","volume":"31","author":"Huss M","year":"2014","unstructured":"Huss M, Ginsberg Y, Tvedten T, et al.. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther. 2014, 31:44-65. 10.1007\/s12325-013-0085-5","journal-title":"Adv Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08144","article-title":"Lisdexamfetamine dimesylate in adults with attention-deficit\/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study","volume":"74","author":"Adler LA","year":"2013","unstructured":"Adler LA, Dirks B, Deas PF, Raychaudhuri A, Dauphin MR, Lasser RA, Weisler RH. Lisdexamfetamine dimesylate in adults with attention-deficit\/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013, 74:694-702. 10.4088\/JCP.12m08144","journal-title":"J Clin Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852900024056","article-title":"Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit\/ hyperactivity disorder","volume":"14","author":"Weisler R","year":"2009","unstructured":"Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit\/ hyperactivity disorder. CNS Spectr. 2009, 14:573-85. 10.1017\/s1092852900024056","journal-title":"CNS Spectr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318192e4a0","article-title":"Once-daily atomoxetine for adult attention-deficit\/hyperactivity disorder: a 6-month, double-blind trial","volume":"29","author":"Adler LA","year":"2009","unstructured":"Adler LA, Spencer T, Brown TE, et al.. Once-daily atomoxetine for adult attention-deficit\/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009, 29:44-50. 10.1097\/JCP.0b013e318192e4a0","journal-title":"J Clin Psychopharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v66n0304","article-title":"Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit\/hyperactivity disorder: an interim analysis","volume":"66","author":"Adler LA","year":"2005","unstructured":"Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit\/hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005, 66:294-9. 10.4088\/jcp.v66n0304","journal-title":"J Clin Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4321\/S0213-61632013000300005","article-title":"Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit\/hyperactivity disorder","volume":"27","author":"Camporeale A","year":"2013","unstructured":"Camporeale A, Upadhyaya H, Ramos-Quiroga JA, et al.. Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit\/hyperactivity disorder. Eur J Psychiat. 2013, 27:206-24. 10.4321\/S0213-61632013000300005","journal-title":"Eur J Psychiat"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12119","article-title":"Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder","volume":"6","author":"Hirata Y","year":"2014","unstructured":"Hirata Y, Goto T, Takita Y, Trzepacz PT, Allen AJ, Ichikawa H, Takahashi M. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Asia Pac Psychiatry. 2014, 6:292-301. 10.1111\/appy.12119","journal-title":"Asia Pac Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12979","article-title":"Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit\/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study","volume":"81","author":"Iwanami A","year":"2020","unstructured":"Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit\/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2020, 81:10.4088\/JCP.19m12979","journal-title":"J Clin Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02867-8","article-title":"Safety and efficacy of guanfacine extended-release in adults with attention-deficit\/hyperactivity disorder: an open-label, long-term, phase 3 extension study","volume":"20","author":"Iwanami A","year":"2020","unstructured":"Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Safety and efficacy of guanfacine extended-release in adults with attention-deficit\/hyperactivity disorder: an open-label, long-term, phase 3 extension study. BMC Psychiatry. 2020, 20:485. 10.1186\/s12888-020-02867-8","journal-title":"BMC Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2010.02159.x","article-title":"An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit\/hyperactivity disorder","volume":"65","author":"Takahashi M","year":"2011","unstructured":"Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit\/hyperactivity disorder. Psychiatry Clin Neurosci. 2011, 65:55-63. 10.1111\/j.1440-1819.2010.02159.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-016-0212-7","article-title":"Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study","volume":"9","author":"Tanaka Y","year":"2017","unstructured":"Tanaka Y, Escobar R, Upadhyaya HP. Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study. Atten Defic Hyperact Disord. 2017, 9:113-20. 10.1007\/s12402-016-0212-7","journal-title":"Atten Defic Hyperact Disord"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1083394","article-title":"Time-to-onset and -resolution of adverse events before\/after atomoxetine discontinuation in adult patients with ADHD","volume":"127","author":"Upadhyaya H","year":"2015","unstructured":"Upadhyaya H, Tanaka Y, Lipsius S, et al.. Time-to-onset and -resolution of adverse events before\/after atomoxetine discontinuation in adult patients with ADHD. Postgrad Med. 2015, 127:677-85. 10.1080\/00325481.2015.1083394","journal-title":"Postgrad Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X154132","article-title":"Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder","volume":"22","author":"Fallu A","year":"2006","unstructured":"Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006, 22:2557-66. 10.1185\/030079906X154132","journal-title":"Curr Med Res Opin"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01120-0","article-title":"An open-label extension study assessing the long-term safety and efficacy of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder","volume":"38","author":"Childress A","year":"2024","unstructured":"Childress A, Cutler AJ, Adler LA, et al.. An open-label extension study assessing the long-term safety and efficacy of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder. CNS Drugs. 2024, 38:891-907. 10.1007\/s40263-024-01120-0","journal-title":"CNS Drugs"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/BF00179957","article-title":"Effects of amphetamine on human nasal mucosa","volume":"253","author":"Wang HW","year":"1996","unstructured":"Wang HW, Wang SH, Wang JY, Su WY. Effects of amphetamine on human nasal mucosa. Eur Arch Otorhinolaryngol. 1996, 253:498-500. 10.1007\/BF00179957","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1947.02890140029007","article-title":"Oral use of stimulants obtained from inhalers","volume":"135","author":"MO RR","year":"1947","unstructured":"MO RR, DR HJ. Oral use of stimulants obtained from inhalers. J Am Med Assoc. 1947, 135:909-15. 10.1001\/jama.1947.02890140029007","journal-title":"J Am Med Assoc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.10.032","article-title":"Bidirectional association between allergic rhinitis and attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis","volume":"369","author":"Wei J","year":"2025","unstructured":"Wei J, Li Y, Wu Q, Lei B, Gui X. Bidirectional association between allergic rhinitis and attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis. J Affect Disord. 2025, 369:499-507. 10.1016\/j.jad.2024.10.032","journal-title":"J Affect Disord"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1281-7","article-title":"Allergic diseases in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis","volume":"17","author":"Miyazaki C","year":"2017","unstructured":"Miyazaki C, Koyama M, Ota E, et al.. Allergic diseases in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis. BMC Psychiatry. 2017, 17:120. 10.1186\/s12888-017-1281-7","journal-title":"BMC Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.603571","article-title":"Understanding the link between allergy and neurodevelopmental disorders: a current review of factors and mechanisms","volume":"11","author":"Chua RX","year":"2020","unstructured":"Chua RX, Tay MJ, Ooi DS, et al.. Understanding the link between allergy and neurodevelopmental disorders: a current review of factors and mechanisms. Front Neurol. 2020, 11:603571. 10.3389\/fneur.2020.603571","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/432604-nasal-adverse-events-associated-with-attention-deficit-hyperactivity-disorder-adhd-medications-a-systematic-review-meta-analysis-and-implications-for-the-otolaryngologist","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:05:08Z","timestamp":1763193908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/432604-nasal-adverse-events-associated-with-attention-deficit-hyperactivity-disorder-adhd-medications-a-systematic-review-meta-analysis-and-implications-for-the-otolaryngologist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.96878","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}